Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

FY2022 Q2 Presentation

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2022

Carna Announces Clearance of IND to Initiate Phase 1b Study of AS-1763 in the U.S.

FY2022 Q1 Presentation

Revision of Results Forecast for the Fiscal Year Ending December 31, 2022

Consolidated Financial Results for the First Quarter of the Year Ending December 31, 2022

Gilead Presented a Novel DGKα Inhibitor Licensed from Carna

Carna Presented AS-1763 Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting